ACADIA PHARMACEUTICALS INC (ACAD)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue Quarterly

0 150M 300M 450M Q1 '10: 2.1M Q2 '10: 2.3M Q3 '10: 2.3M Q4 '10: 35.4M Q1 '11: 435K Q2 '11: 460K Q3 '11: 584K Q4 '11: 588K Q1 '12: 450K Q2 '12: 599K Q3 '12: 3.5M Q4 '12: 380K Q1 '13: 417K Q2 '13: 451K Q3 '13: 240K Q4 '13: 37K Q1 '14: 30K Q2 '14: 28K Q3 '14: 15K Q4 '14: 47K Q1 '15: 4K Q2 '15: 1K Q3 '15: 39K Q4 '15: 17K Q1 '16: 4K Q2 '16: 97K Q3 '16: 5.3M Q4 '16: 12M Q1 '17: 15.3M Q2 '17: 30.5M Q3 '17: 35.6M Q4 '17: 43.6M Q1 '18: 48.9M Q2 '18: 57.1M Q3 '18: 58.3M Q4 '18: 59.6M Q1 '19: 63M Q2 '19: 83.2M Q3 '19: 94.6M Q4 '19: 98.3M Q1 '20: 90.1M Q2 '20: 110.1M Q3 '20: 120.6M Q4 '20: 121M Q4 '20: 121M Q1 '21: 106.6M Q2 '21: 115.2M Q3 '21: 131.6M Q4 '21: 130.8M Q1 '22: 115.5M Q2 '22: 134.6M Q3 '22: 130.7M Q4 '22: 136.5M Q1 '23: 118.5M Q2 '23: 165.2M Q3 '23: 211.7M Q4 '23: 231M Q1 '24: 205.8M Q2 '24: 242M Q3 '24: 250.4M Q4 '24: 259.6M Q1 '25: 244.3M Q2 '25: 264.6M Q3 '25: 278.6M Q4 '25: 284M Q1 '26: 268.1M Q2 '26: 308M Q4 '10 Q1 '13 Q2 '15 Q3 '17 Q4 '19 Q4 '21 Q1 '24 Q2 '26

Gross Profit Quarterly

-80M 0 80M 160M 240M Q1 '16: 0 Q2 '16: -429K Q3 '16: 4.4M Q4 '16: 10.3M Q1 '17: 13M Q2 '17: 28.3M Q3 '17: 33.4M Q4 '17: 41.1M Q1 '18: 46.7M Q2 '18: 53.5M Q3 '18: 54.5M Q4 '18: 56.7M Q1 '19: 60M Q2 '19: 80.2M Q3 '19: 92.2M Q4 '19: 95.3M Q1 '20: 87.3M Q2 '20: 107.2M Q3 '20: 118.6M Q4 '20: 118.5M Q1 '21: 104.4M Q2 '21: 112.7M Q3 '21: 127.9M Q4 '21: 128.3M Q1 '22: 112.5M Q2 '22: 131.9M Q3 '22: 128.6M Q4 '22: 134.1M Q1 '23: 116.8M Q2 '23: 157.8M Q3 '23: 197.1M Q4 '23: 213.2M Q4 '16 Q4 '17 Q4 '18 Q4 '19 Q4 '20 Q4 '21 Q4 '22 Q4 '23

Operating Income Quarterly

-120M -60M 0 60M 120M 180M Q1 '10: -5.5M Q2 '10: -4.3M Q3 '10: -4.2M Q4 '10: 29.1M Q1 '11: -5.9M Q2 '11: -6.6M Q3 '11: -5.1M Q4 '11: -5.3M Q1 '12: -6.2M Q2 '12: -5.4M Q3 '12: -2.4M Q4 '12: -6.8M Q1 '13: -6.2M Q2 '13: -9.2M Q3 '13: -10.8M Q4 '13: -12.2M Q1 '14: -18M Q2 '14: -21.7M Q3 '14: -25M Q4 '14: -28.6M Q1 '15: -40.6M Q2 '15: -39.5M Q3 '15: -39M Q4 '15: -45.6M Q1 '16: -50.3M Q2 '16: -71.9M Q3 '16: -72.4M Q4 '16: -78.2M Q1 '17: -88.7M Q2 '17: -68M Q3 '17: -65.6M Q4 '17: -70M Q1 '18: -54.8M Q2 '18: -64.1M Q3 '18: -61.3M Q4 '18: -67.3M Q1 '19: -87.6M Q2 '19: -57.1M Q3 '19: -45.4M Q4 '19: -56.4M Q1 '20: -89.5M Q2 '20: -44M Q3 '20: -85.9M Q4 '20: -67.2M Q1 '21: -66.8M Q2 '21: -43.7M Q3 '21: -15.3M Q4 '21: -44.7M Q1 '22: -113M Q2 '22: -33.7M Q3 '22: -30.9M Q4 '22: -46.1M Q1 '23: -53.6M Q2 '23: 3M Q3 '23: -57.8M Q4 '23: 34.9M Q1 '24: 15.2M Q2 '24: 30.4M Q3 '24: 31.6M Q4 '24: 153.5M Q1 '25: 19.3M Q2 '25: 32.4M Q3 '25: 35.8M Q4 '25: 17.4M Q1 '26: -4.6M Q2 '26: 37.8M Q3 '10 Q4 '12 Q1 '15 Q2 '17 Q3 '19 Q4 '21 Q1 '24 Q2 '26

Net Income Quarterly

-200M -100M 0 100M 200M 300M Q1 '10: -5.5M Q2 '10: -4.3M Q3 '10: -4.2M Q4 '10: 29.1M Q1 '11: -5.8M Q2 '11: -6.6M Q3 '11: -5.1M Q4 '11: -5.3M Q1 '12: -6.2M Q2 '12: -5.4M Q3 '12: -2.4M Q4 '12: -6.8M Q1 '13: -6.1M Q2 '13: -9.1M Q3 '13: -10.7M Q4 '13: -12M Q1 '14: -17.8M Q2 '14: -21.5M Q3 '14: -24.8M Q4 '14: -28.4M Q1 '15: -40.4M Q2 '15: -39.4M Q3 '15: -38.9M Q4 '15: -45.8M Q1 '16: -49.8M Q2 '16: -71.3M Q3 '16: -71.6M Q4 '16: -78.7M Q1 '17: -87.8M Q2 '17: -67.4M Q3 '17: -65.2M Q4 '17: -68.9M Q1 '18: -54.3M Q2 '18: -63.3M Q3 '18: -62.1M Q4 '18: -65.5M Q1 '19: -85.3M Q2 '19: -54.9M Q3 '19: -42M Q4 '19: -53M Q1 '20: -88M Q2 '20: -42.1M Q3 '20: -84.7M Q4 '20: -66.8M Q4 '20: -66.8M Q1 '21: -66.4M Q2 '21: -43.9M Q3 '21: -14.5M Q4 '21: -43.1M Q1 '22: -113.1M Q2 '22: -34M Q3 '22: -27.2M Q4 '22: -41.7M Q1 '23: -43M Q2 '23: 1.1M Q3 '23: -65.2M Q4 '23: 45.8M Q1 '24: 16.6M Q2 '24: 33.4M Q3 '24: 32.8M Q4 '24: 143.7M Q1 '25: 19M Q2 '25: 26.7M Q3 '25: 71.8M Q4 '25: 273.6M Q1 '26: 3.6M Q2 '26: 31.5M Q4 '10 Q1 '13 Q2 '15 Q3 '17 Q4 '19 Q4 '21 Q1 '24 Q2 '26

Cost of Revenue Quarterly

0 10M 20M 30M Q1 '17: 2.3M Q2 '17: 2.2M Q3 '17: 2.1M Q4 '17: 2.5M Q1 '18: 2.2M Q2 '18: 3.6M Q3 '18: 3.8M Q4 '18: 2.8M Q1 '19: 3M Q2 '19: 3M Q3 '19: 2.4M Q4 '19: 3M Q1 '20: 2.8M Q2 '20: 2.9M Q3 '20: 2M Q4 '20: 2.5M Q1 '21: 2.2M Q2 '21: 2.5M Q3 '21: 3.7M Q4 '21: 10.7M Q1 '22: 3M Q2 '22: 2.7M Q3 '22: 2.1M Q4 '22: 2.4M Q1 '23: 1.7M Q2 '23: 7.5M Q3 '23: 14.6M Q4 '23: 17.9M Q1 '24: 23M Q2 '24: 18.2M Q3 '24: 18.9M Q4 '24: 21.8M Q1 '25: 20.4M Q2 '25: 20.7M Q3 '25: 21.6M Q4 '25: 26.2M Q1 '26: 24.8M Q2 '26: 28.3M Q3 '17 Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Operating Cash Flow Quarterly

-105M -70M -35M 0 35M 70M 105M Q3 '10: -2.5M Q1 '11: -5.1M Q2 '11: -5.3M Q3 '11: -4.2M Q4 '11: -5.3M Q1 '12: -5.2M Q2 '12: -4.8M Q3 '12: -5.3M Q4 '12: -6.3M Q1 '13: -6.6M Q2 '13: -5.4M Q3 '13: -9.5M Q4 '13: -10.3M Q1 '14: -14.2M Q2 '14: -17M Q3 '14: -17.5M Q4 '14: -17.8M Q1 '15: -25.3M Q2 '15: -29.9M Q3 '15: -31.9M Q4 '15: -34.7M Q1 '16: -41.2M Q2 '16: -56.7M Q3 '16: -49.3M Q4 '16: -63.2M Q1 '17: -70.6M Q2 '17: -59M Q3 '17: -58.4M Q4 '17: -29.9M Q1 '18: -45.2M Q2 '18: -40.9M Q3 '18: -42.3M Q4 '18: -39.1M Q1 '19: -64.2M Q2 '19: -38.4M Q3 '19: -18.9M Q4 '19: -29.7M Q1 '20: -49M Q2 '20: -36.9M Q3 '20: -22.8M Q4 '20: -27.5M Q1 '21: -60.1M Q2 '21: -25.3M Q3 '21: -17.1M Q4 '21: -23.1M Q1 '22: -76.3M Q2 '22: -13.1M Q3 '22: -727K Q4 '22: -23.9M Q1 '23: -17.9M Q2 '23: 8.2M Q3 '23: -59M Q1 '24: 29.1M Q2 '24: 25M Q3 '24: 63.2M Q4 '24: 40.4M Q1 '25: 20.3M Q2 '25: 64M Q3 '25: 74.3M Q1 '26: 34M Q2 '26: 100.8M Q4 '11 Q4 '13 Q4 '15 Q4 '17 Q4 '19 Q4 '21 Q1 '24 Q2 '26

Free Cash Flow Quarterly

-105M -70M -35M 0 35M 70M 105M Q3 '13: -9.9M Q4 '13: -10.4M Q1 '14: -14.2M Q2 '14: -17M Q3 '14: -17.6M Q4 '14: -17.9M Q1 '15: -26.3M Q2 '15: -30.5M Q3 '15: -32M Q4 '15: -35M Q1 '16: -41.4M Q2 '16: -57.3M Q3 '16: -49.7M Q4 '16: -63.4M Q1 '17: -71M Q2 '17: -59.3M Q3 '17: -58.5M Q4 '17: -29.9M Q1 '18: -45.7M Q2 '18: -41M Q3 '18: -43.3M Q4 '18: -39.6M Q1 '19: -65M Q2 '19: -38.4M Q3 '19: -18.9M Q4 '19: -29.9M Q1 '20: -49.9M Q2 '20: -39.8M Q3 '20: -24.5M Q4 '20: -29.5M Q1 '21: -61.2M Q2 '21: -25.4M Q3 '21: -17.1M Q4 '21: -23.1M Q1 '22: -76.3M Q2 '22: -13.1M Q3 '22: -727K Q4 '22: -23.9M Q3 '24: 63.2M Q4 '24: 39.9M Q1 '25: 20.3M Q2 '25: 63.7M Q3 '25: 73.9M Q1 '26: 28.8M Q2 '26: 95.7M Q1 '14 Q3 '15 Q1 '17 Q3 '18 Q1 '20 Q3 '21 Q3 '24 Q2 '26

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 60M 120M 180M Q2 '21: 160.4K Q3 '21: 160.7K Q1 '22: 161.2M Q2 '22: 161.7K Q3 '22: 161.9K Q1 '23: 162.3M Q2 '23: 165M Q3 '23: 164.2M Q1 '24: 166.6M Q2 '24: 166.2M Q3 '24: 166.2M Q1 '25: 167.7M Q2 '25: 168.7M Q3 '25: 170.7M Q1 '26: 172.7M Q2 '26: 172.9M Q3 '21 Q2 '22 Q1 '23 Q3 '23 Q2 '24 Q1 '25 Q3 '25 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-2.70 -1.80 -0.90 0.00 0.90 1.80 2.70 Q4 '11: -0.44 Q1 '12: -0.44 Q2 '12: -0.42 Q3 '12: -0.36 Q4 '12: -0.37 Q1 '13: -0.33 Q2 '13: -0.34 Q3 '13: -0.42 Q4 '13: -0.44 Q1 '14: -0.55 Q2 '14: -0.66 Q3 '14: -0.79 Q4 '14: -0.94 Q1 '15: -1.15 Q2 '15: -1.32 Q3 '15: -1.46 Q4 '15: -1.63 Q1 '16: -1.68 Q2 '16: -1.92 Q3 '16: -2.14 Q4 '16: -2.34 Q1 '17: -2.61 Q2 '17: -2.53 Q3 '17: -2.45 Q4 '17: -2.35 Q1 '18: -2.07 Q2 '18: -2.03 Q3 '18: -2.00 Q4 '18: -1.95 Q1 '19: -2.10 Q2 '19: -1.97 Q3 '19: -1.76 Q4 '19: -1.60 Q1 '20: -1.58 Q2 '20: -1.47 Q3 '20: -1.72 Q4 '20: -1.80 Q3 '23: -0.92 Q4 '23: -0.38 Q1 '24: -0.01 Q2 '24: 0.18 Q3 '24: 0.78 Q4 '24: 1.36 Q1 '25: 1.37 Q2 '25: 1.33 Q3 '25: 1.55 Q4 '25: 2.30 Q1 '26: 2.21 Q2 '26: 2.23 Q2 '13 Q1 '15 Q4 '16 Q3 '18 Q2 '20 Q3 '24 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.